A fresh controversy has erupted over the reuse of a previously banned immunoglobulin vaccine, with serious allegations surfacing against Sri Lanka’s health authorities. Dr. Chamal Sanjeewa, Chairman of the Doctors’ Trade Union Alliance for Medical and Civil Rights, claims that the Medical Supplies Division has instructed hospitals to resume the use of a batch of immunoglobulin drugs that had earlier been withdrawn due to safety concerns.
Dr. Sanjeewa made the accusation after lodging a formal complaint with the Commission to Investigate Allegations of Bribery or Corruption. The complaint centers on what he describes as deliberate delays in the registration of low-cost pharmaceutical suppliers and the awarding of drug import contracts to companies quoting higher prices.
The immunoglobulin antibody drug in question had sparked concern during its use in Sri Lankan hospitals after reports of allergic reactions and complications. The controversy gained significant public attention when it was revealed that the vaccine had been procured under the tenure of former Health Minister Keheliya Rambukwella, who was subsequently arrested and remanded over the matter.
In response to Dr. Sanjeewa’s claims, the National Medicines Regulatory Authority (NMRA) issued a statement seeking to clarify the situation. According to the NMRA, the vaccine—registered in 2023 under the name Immunoglobulin—was temporarily pulled from use after complaints were received regarding adverse reactions. Following these complaints, the Safety and Risk Assessment Subcommittee advised the Medical Supplies Division to suspend its distribution pending further investigation.
However, subsequent testing conducted by both the NMRA and the Central Institute of Medicines Quality Control in India confirmed that the vaccine met all quality standards. As a result, the Safety and Risk Assessment Subcommittee—comprising leading medical specialists—has now determined that the immunoglobulin vaccine is safe for continued use.
“The NMRA wishes to assure the public and medical professionals that there is no reason to doubt the quality of the drug,” the statement emphasized. “Based on thorough investigation and expert opinion, it has been recommended that the vaccine can be reused without risk.”
Despite this assurance, Dr. Sanjeewa remains critical, alleging that the decision to reintroduce the vaccine lacks transparency and undermines public trust in the healthcare system. The matter continues to stir debate among medical professionals and policymakers, particularly in light of broader concerns over drug procurement practices and political interference in the health sector.
